PPR-005 - Methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder: Experience of Australian clinicians, researchers and patients

• At: Copenhagen (Denmark) (2025)
• Type: Poster
• Poster code: PPR-005
• By: YONG, Alene (Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Australia)
• Co-author(s): Dr Alene Yong (Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, Australia)
  Ms Aimee Freeburn (Neuromedicines Discovery Centre, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Australia)
  Ms Suzie Bratuskins (Neuromedicines Discovery Centre, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Australia)
  Professor J Simon Bell (Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, Australia)
  
• Abstract:

  Background information: Australia is the first country in the world to reschedule methylenedioxymethamphetamine (MDMA) to permit authorised prescribing of MDMA for Post-traumatic Stress Disorder (PTSD) outside of the clinical trial setting. However, gaps remain regarding the translation of research evidence into clinical practice.
  
  Purpose: The..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login